权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Developmental Clinical Studies - Curing Obesity with the 'Medical Bypass'

发育临床研究 - 通过“医疗旁路”治愈肥胖

基本信息

批准号：
MR/J010731/1
负责人：
Stephen Bloom
金额：
$ 378.22万
依托单位：
Imperial College London
依托单位国家：
英国
项目类别：
Research Grant
财政年份：
2013
资助国家：
英国
起止时间：
2013 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=MR%2FJ010731%2F1
关键词：
Developmental Clinical Studies Curing Obesity

项目摘要

A quarter of the UK population is obese and unfortunately this number is still rising. Obesity is strongly associated with maturity onset diabetes. Obesity is also a major cause of cancer, heart attacks, strokes and other illnesses. There is no effective drug therapy for obesity. The only effective treatment is gastric bypass surgery which causes a large weight loss, cure of diabetes and a reduction of rates of cancer and heart attacks. Unfortunately surgery is a major undertaking, is expensive, is irreversible, is associated with complications, and is risky. The benefits of this surgery are due to the much increased secretion of chemicals by the gut, called gut hormones. These are glucagon-like peptide-1, oxyntomodulin and peptide YY. We have developed two new drugs based on these gut hormones, made with natural amino acids, and combined them together to mimic the effect of bypass surgery in a single weekly injection through a fine needle. We call this the 'medical bypass' as it works by the same mechanism as the surgical bypass. This treatment will be as effective as bypass surgery but it will be less expensive and will be much less risky. One of the components of the medical bypass, which we call Y242, is already being tested in trials this year. In the project here, we are going to develop the other component, which we call G3215. We will first test G3215 to make sure it is safe before testing it in human volunteers to check that it is well-tolerated. We will then mix the Y242 and G3215 together and test this in human volunteers, as well as in patients with diabetes, to prove that the medical bypass is effective in helping patients lose weight and control their blood sugar levels. If our medical bypass is effective, this would be a great advance in the treatment of obesity and diabetes, and would help to save the many lives lost each year to the complications of these serious conditions.

英国四分之一的人口肥胖，不幸的是，这一数字仍在上升。肥胖与成熟期糖尿病密切相关。肥胖也是癌症、心脏病、中风和其他疾病的主要原因。肥胖症没有有效的药物治疗。唯一有效的治疗方法是胃旁路手术，这会导致大量的体重减轻，治愈糖尿病，降低癌症和心脏病发作的发病率。不幸的是，手术是一项重大的事业，昂贵，不可逆，与并发症有关，并且有风险。这种手术的好处是由于肠道分泌的化学物质大大增加，称为肠道激素。它们是胰高血糖素样肽-1、胃泌酸调节素和肽YY。我们已经开发了两种基于这些肠道激素的新药，用天然氨基酸制成，并将它们结合在一起，通过细针每周一次注射来模拟搭桥手术的效果。我们称之为“医疗旁路”，因为它的工作原理与外科旁路相同。这种治疗方法与搭桥手术一样有效，但费用更低，风险也更小。医疗旁路的一个组成部分，我们称之为Y242，今年已经在试验中进行测试。在这个项目中，我们将开发另一个组件，我们称之为G3215。我们将首先测试G3215，以确保它是安全的，然后在人类志愿者中进行测试，以检查它是否耐受良好。然后，我们将Y242和G3215混合在一起，并在人类志愿者和糖尿病患者中进行测试，以证明医疗旁路可以有效帮助患者减肥和控制血糖水平。如果我们的医疗旁路是有效的，这将是治疗肥胖和糖尿病的一个巨大进步，并将有助于挽救每年因这些严重疾病的并发症而失去的许多生命。

项目成果

期刊论文数量（10）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Degradation Paradigm of the Gut Hormone, Pancreatic Polypeptide, by Hepatic and Renal Peptidases.

DOI：
10.1210/en.2016-1827
发表时间：
2017-06-01
期刊：
Endocrinology
影响因子：
4.8
作者：
Cuenco J;Minnion J;Tan T;Scott R;Germain N;Ling Y;Chen R;Ghatei M;Bloom S
通讯作者：
Bloom S

Pharmacokinetics and pharmacodynamics of subcutaneously administered PYY3-36 and its analogues in vivo.

DOI：
10.1016/s0140-6736(15)60343-9
发表时间：
2015-02-26
期刊：
Lancet (London, England)
影响因子：
0
作者：
Cegla, Jaimini;Cuenco, Joyceline;Bloom, Stephen
通讯作者：
Bloom, Stephen

Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss.

DOI：
10.1016/j.xcrm.2022.100810
发表时间：
2022-11-15
期刊：
CELL REPORTS MEDICINE
影响因子：
14.3
作者：
Hope, David C. D.;Hinds, Charlotte E.;Lopes, Tatiana;Vincent, Matthew L.;V. Shrewsbury, Jed;Yu, Arthur T. C.;Davies, Iona;Scott, Rebecca;Jones, Ben;Murphy, Kevin G.;Minnion, James S.;Sardini, Alessandro;Carling, David;Lutz, Thomas A.;Bloom, Stephen R.;Tan, Tricia M. M.;Owen, Bryn M.
通讯作者：
Owen, Bryn M.

RAMP2 Influences Glucagon Receptor Pharmacology via Trafficking and Signaling.

DOI：
10.1210/en.2016-1755
发表时间：
2017-08-01
期刊：
Endocrinology
影响因子：
4.8
作者：
Cegla J;Jones BJ;Gardiner JV;Hodson DJ;Marjot T;McGlone ER;Tan TM;Bloom SR
通讯作者：
Bloom SR

A glucagon analogue decreases body weight in mice via signalling in the liver.

DOI：
10.1038/s41598-021-01912-0
发表时间：
2021-11-19
期刊：
Scientific reports
影响因子：
4.6
作者：
Hinds CE;Owen BM;Hope DCD;Pickford P;Jones B;Tan TM;Minnion JS;Bloom SR
通讯作者：
Bloom SR

DOI：
{{ item.doi }}
发表时间：
{{ item.publish_year }}
期刊：
{{ item.journal_name }}
影响因子：
{{ item.factor }}
作者：
{{ item.authors }}
通讯作者：
{{ item.author }}

数据更新时间：{{ journalArticles.updateTime }}

作者：
{{ item.author }}

数据更新时间：{{ monograph.updateTime }}

作者：
{{ item.author }}

数据更新时间：{{ sciAawards.updateTime }}

作者：
{{ item.author }}

数据更新时间：{{ conferencePapers.updateTime }}

作者：
{{ item.author }}

数据更新时间：{{ patent.updateTime }}

Stephen Bloom其他文献

Nomination and list placement of ethnic minorities under open-list proportional rules: The centrality of ethnopolitical context

开放名单比例规则下少数民族的提名和名单安排：民族政治背景的中心地位

DOI：
10.1016/j.electstud.2021.102386
发表时间：
2021
期刊：
Electoral Studies
影响因子：
2.3
作者：
Stephen Bloom;F. Thames
通讯作者：
F. Thames

The 2010 Latvian parliamentary elections

DOI：
10.1016/j.electstud.2011.03.003
发表时间：
2011-06-01
期刊：
Short communication
影响因子：
作者：
Stephen Bloom
通讯作者：
Stephen Bloom

WED-244 Evaluation of the Baveno VII criteria for predicting liver-related events in patients with advanced chronic liver disease – a single centre retrospective study

WED - 244对Baveno VII标准用于预测晚期慢性肝病患者肝脏相关事件的评估——一项单中心回顾性研究

DOI：
10.1016/s0168-8278(25)00841-4
发表时间：
2025-05-01
期刊：
JOURNAL OF HEPATOLOGY
影响因子：
33.000
作者：
Steven Trinh;Qing Fang;Estelle Sultana;Kimberley Eu;Alice Comsa;Emily Schembri;Stephen Bloom;Rohit Sawhney
通讯作者：
Rohit Sawhney

FRI090 - Increased liver stiffness on vibration controlled transient elastography (Fibroscan) as a predictor of all-cause mortality in people with fatty liver disease

FRI090 - 振动控制瞬时弹性成像（Fibroscan）显示的肝脏硬度增加可作为脂肪肝患者全因死亡率的预测指标

DOI：
10.1016/s0168-8278(22)01219-3
发表时间：
2022-07-01
期刊：
JOURNAL OF HEPATOLOGY
影响因子：
33.000
作者：
Michael Braude;Ammar Majeed;Stuart Roberts;Stephen Bloom;Paul Gow;Anouk Dev;William Sievert;William Kemp
通讯作者：
William Kemp

ACR Appropriateness Criteria® Evaluation of Coronary Artery Anomalies

ACR 适宜性标准®冠状动脉异常的评估

DOI：
10.1016/j.jacr.2025.02.030
发表时间：
2025-05-01
期刊：
Journal of the American College of Radiology
影响因子：
5.100
作者：
Expert Panel on Cardiac Imaging;Cristina Fuss;Raluca McCallum;Brian B. Ghoshhajra;Diana Litmanovich;Prachi P. Agarwal;Stephen Bloom;William M. Brown;Anjali Chelliah;Carlo N. De Cecco;Peter Frommelt;Kimberly Kallianos;Sachin B. Malik;Constantine D. Mavroudis;Nandini M. Meyersohn;Sven Plein;Tina D. Tailor;Chadwick L. Wright;Lynne M. Koweek
通讯作者：
Lynne M. Koweek